The efficacy of clobetasol, dexpanthenol, and fucidic acid in the treatment of cetuximab-induced skin toxicity
Cetuximab (CTX) is a monoclonal antibody against the epidermal growth factor receptor (EGFR). It is used as a monotherapy or in combination with cytotoxic chemotherapy in metastatic colorectal cancer (mCRC). Severe cutaneous reactions are frequent and major causes of discontinuation of CTX treatment...
Main Author: | Didem Tastekin |
---|---|
Format: | Article |
Language: | English |
Published: |
Society of Turaz Bilim
2017-06-01
|
Series: | Medicine Science |
Subjects: | |
Online Access: | http://www.ejmanager.com/fulltextpdf.php?mno=247238 |
Similar Items
-
EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
by: Andrea Uhlyarik, et al.
Published: (2020-03-01) -
Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
by: G. Martini, et al.
Published: (2023-04-01) -
Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Yi-Chia Su, et al.
Published: (2022-04-01) -
The Effect of Topical Vitamin K1 on the Treatment of Cetuximab-Induced Skin Rashes in Metastatic Colorectal Cancer Patients
by: Mahnaz Roayaei, et al.
Published: (2023-01-01) -
The Riddle of Cetuximab-Related Skin Toxicity: <sup>1</sup>H-NMR Sebum Analysis Revealed Dynamic Lipid Alterations Associated with Skin Toxicity Development in Metastatic Colorectal Cancer Patients
by: Asia Saorin, et al.
Published: (2022-10-01)